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ABSTRACT: MUC1 mucin is a breast cancer-associated transmembrane glycoprotein, of which the
extracellular domain is formed by the repeating 20-amino acid sequence GVTSAPDTRPAPGSTAPPAH.
In neoplastic breast tissue, the highly immunogenic sequence PDTRPAP (in bold above) is exposed.
Antibodies raised directly against MUC1-expressing tumors offer unique access to this neoplastic state,
as they represent immunologically relevant “reverse templates” of the tumor-associated mucin. In a previous
study [Grinstead, J. S.,et al. (2002)Biochemistry 41, 9946-9961],1H NMR methods were used to correlate
the effects of cryptic glycosylation outside of the PDTRPAP core epitope sequence on the recognition
and binding of Mab B27.29, a monoclonal antibody raised against breast tumor cells. In the study presented
here, isotope-edited NMR methods, including15N and13C relaxation measurements, were used to probe
the recognition and binding of the PDTRPAP epitope sequence to Fab B27.29. Two peptides were
studied: a one-repeat MUC1 16mer peptide of the sequence GVTSAPDTRPAPGSTA and a two-repeat
MUC1 40mer peptide of the sequence (VTSAPDTRPAPGSTAPPAHG)2. 15N and13C NMR relaxation
parameters were measured for both peptides free in solution and bound to Fab B27.29. The13CR T1 values
best represent changes in the local correlation time of the peptide epitope upon binding antibody, and
demonstrate that the PDTRPAP sequence is immobilized in the antibody-combining site. This result is
also reflected in the appearance of the15N- and13C-edited HSQC spectra, where line broadening of the
same peptide epitope resonances is observed. The PDTRPAP peptide epitope expands upon the peptide
epitope identified previously in our group as PDTRP by homonuclear NMR experiments [Grinstead, J.
S., et al. (2002)Biochemistry 41, 9946-9961], and illustrates the usefulness of the heteronuclear NMR
experiments. The implications of these results are discussed within the context of MUC1 breast cancer
vaccine design.
Mucins have been implicated as targets for vaccine
development in cancers of the breast, colon, pancreas, lung,
and ovary because of the differences between normal and
tumor-associated mucin (1-4). Mucin 1 (MUC1)1 is a large
transmembrane glycoprotein that is expressed on the ductal
surface of epithelial cells. The extracellular region of the
protein consists of a variable number of tandem repeats
(VNTR) of the 20-amino acid sequence (GVTSAPDTR-
PAPGSTAPPAH)n, extensively O-glycosylated at threonine
and serine sites with large, branched sugars (5-8). However,
in the tumor-associated state, MUC1 becomes an autoantigen
as a result of incomplete glycosylation and the sparse
distribution of remaining carbohydrate structures (9). The
reduced level of glycosylation is believed to result in the
exposure of a highly immunogenic core peptide sequence
(PDTRP in bold above) (10), identified as the immunodomi-
nant B-cell epitope from monoclonal antibody studies in mice
(11-15). This PDTRP core peptide sequence is also believed
to be immunodominant in humans. Breast cancer patients
with MUC1-expressing tumors develop limited humoral and
cellular immune responses against the tumor (16-18), with
the elicited antibodies and T-cells cross-reactive to the
PDTRP core peptide sequence (19-21).
Many different clinical trials have been undertaken over
the past few years to assess the ability of MUC1-based
vaccines to generate strong and cytotoxic anti-MUC1 im-
mune responses against the solid MUC1-expressing tumor.
Several of these trials have explored the use of MUC1
peptides coupled to different haptens, keyhole limpet hemocy-
anin, oxidized mannan, and glutathioneS-transferase (4). In
addition, at least two different vaccine trials have used
MUC1-associated antigenic sugars (without peptide) (22 .
Other more recent clinical trials have utilized peptide- or
DNA-pulsed dendritic cells as vaccine vectors, attempting
to capitalize on the superior immune activation by these
antigen-presenting cells. Dendritic cells pulsed with either
MUC1 peptides or cDNA have been able to generate limited
CD8+ T-cell responses to solid breast tumors (23, 24),
although these responses did not result in tumor rejection.
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Indeed, none of the MUC1 vaccine candidates described
above have been shown to be effective at tumor rejection,
although the reasons for this are not absolutely clear (25-
29).
The failure of MUC1-based vaccines to generate effective
immune responses may stem from the use of vaccine
candidates that do not represent the structure, dynamics,
peptide epitope exposure, or even glycosylation state of the
tumor-associated mucin. For example, vaccination with a
MUC1 peptide is unlikely to generate an immune response
to the heavily glycosylated region of the extracellular domain
of MUC1 on the surface of healthy epithelial cells. While
this situation should limit the possibility of an autoimmune
response against healthy epithelial tissues, it is also unlikely
to lead to a strong tumor-specific immune response against
the partially glycosylated tumor-associated MUC1 protein.
In an effort to better characterize the glycosylation state
and peptide epitope exposure of the tumor-associated MUC1
protein, manyin Vitro andin ViVo glycosylation studies have
been undertaken.In Vitro glycosylation studies using human
tumor cell extracts (30-32) have demonstrated the presence
of cryptic carbohydrate structures at only three sites in the
sequence (GVTSA and GSTAP), and not at the central
threonine within the PDTRP core peptide epitope region.
However, recentin ViVo studies have demonstrated that all
five sites are glycosylation targets in the tumor cell (33, 34).
Thus, the glycosylation state of the tumor-associated MUC1
mucin remains indeterminate at present. Furthermore, while
spectroscopic techniques such as NMR and CD have
identified nativeâ-turn secondary structure in unglycosylated
MUC1 (35-40), these studies have not been extrapolated
to the intact partially glycosylated MUC1 protein as it exists
in situ on the tumor cell surface. In the absence of a clear
and definitive picture of the MUC1 mucin in its tumor-
associated state, the design of a peptide or glycopeptide
vaccine that mimics this “unknown” state is a difficult
undertaking.
To circumnavigate this difficulty, we propose an approach
that does not rely ona priori knowledge of the peptide
conformation or glycosylation state for the tumor-associated
MUC1 mucin. This alternative approach involves the use of
an anti-MUC1 antibody, Mab B27.29, as a “reverse template”
for MUC1 vaccine design. Mab B27.29 was raised directly
against MUC1-expressing tumors, so should bind most
tightly to a MUC1 peptide or glycopeptide that best ap-
proximates the structure, dynamics, and glycosylation state
of the tumor-associated mucin. As such, Mab B27.29 is an
immunologically relevant reverse template of the structure,
dynamics, and chemistry of the tumor-associated MUC1
mucin. In brief, this approach identifies the immunologically
relevant peptide conformation and glycosylation states of the
tumor-associated MUC1 mucin by probing the structure and
dynamics of MUC1 peptide-Mab B27.29 recognition and
binding. Solution-state NMR is used as the probe in these
systems, as it allows both structure and dynamics information
to be obtained for the bound state, even if that bound state
is dynamic and conformationally heterogeneous.
Using this NMR-based approach, we recently completed
a homonuclear NMR study examining the effect of glyco-
sylation on Fab B27.29 recognition of a series of 16-residue
MUC1 glycopeptides of the sequence GVTSAPDTRPAPG-
STA (37). The results of this study showed that the B27.29
epitope maps to two separate parts of the glycopeptide, the
core peptide epitope spanning the PDTRP sequence and a
second (carbohydrate) epitope comprised of two cryptic
carbohydrate moieties attached at Thr3 and Ser4 in the 16mer
sequence. The results of this study also showed that the
peptide and carbohydrate epitopes bind independently of each
other to Fab B27.29, prompting us to further explore the
contributions of each epitope separately. In the study
presented here, we extend our NMR-based approach to
include heteronuclear NMR studies of the role of peptide
structure and dynamics on Fab B27.29 recognition of the
same 16-residue MUC1 peptide, as well as of a 40-residue
MUC1 peptide [(VTSAPDTRPAPGSTAPPAHG)2] that rep-
resents two repeats of the MUC1 sequence. Future studies
will continue this line of research in an effort to analyze the
role of carbohydrate structure and dynamics in glycopeptide-
antibody recognition.
NMR studies probing the structure and dynamics of
the 16- and 40-residue MUC1 peptides in free versus Fab-
bound states are significantly facilitated by our ability to
generate isotopically labeled recombinant peptides. This
allows for the acquisition of isotope-edited NMR experiments
of the MUC1 peptide-B27.29 antibody complex, offering
a significant increase in the amount of information relative
to our previous efforts with simple homonuclear NMR
experiments. Included in this study are two-dimensional
isotope-edited NMR experiments, as well as heteronuclear
NMR relaxation measurements, monitoring the binding of
the isotopically labeled MUC1 peptides to the unlabeled Fab
fragment of B27.29. These experiments allow a precise
mapping of the boundary of the B27.29 epitope, based on a
determination of the immobilized portion of the peptide as
it is bound within the B27.29 antibody-combining site. The
results of these studies are discussed within the framework
of developing a second-generation MUC1 peptide vaccine
that better represents the peptide portion of the tumor-
associated MUC1 mucin, as it is recognizedin situ by
B27.29.
MATERIALS AND METHODS
Peptide and Fab Samples. Fab (∼50 kDa) was generated
by papain and pepsin cleavage of IgG B27.29, and was a
generous gift from Biomira Inc. (Edmonton, AB).
Cloning of 16mer and 40mer Peptides. Two MUC1
sequences derived from the extracellular domain of the
MUC1 protein were cloned and expressed for the purposes
of this study: (1) a one-repeat 16mer MUC1 sequence (Gly1-
Val2-Thr3-Ser4-Ala5-Pro6-Asp7-Thr8-Arg9-Pro10-Ala11-





Ala35-Pro36-Pro37-Ala38-His39-Gly40). These two 16mer
and 40mer MUC1 sequences were expressed as15N- and
13C-labeled recombinant peptides inEscherichia coliusing
a methodology described previously (41). Briefly, genes with
multiple repeats of MUC1 DNA sequences were constructed
from purchased oligonucleotides, purified, and ligated into
plasmid DNA vector pET-31b(+). The MUC1 16mer and
40mer DNA-containing plasmids were separately trans-





































































formed into the competentE. coli BLR(DE3) strain for
protein expression. Isotopically15N- and13C-labeled peptides
were then expressed by growing the transformed bacteria in
minimal medium containing M9 salts, and with15NH4Cl and
[13C6]glucose as the sole sources of nitrogen and carbon,
respectively. Isotopically labeled minimal medium was
inoculated at an OD600 of 0.1 from an overnight culture, and
grown to an OD600 of 0.6-0.8 before induction of protein
expression with 1 mM IPTG. Induced cultures were grown
overnight before cells were harvested by centrifugation.
Harvested cell pellets were lysed by sonication, and the
insoluble fraction was collected by centrifugation. The
insoluble fraction was washed several times with Tris buffer
(50 mM, pH 8), and then solubilized using 4 M guanidine
hydrochloride-containing Tris buffer. The solubilized fusion
protein was purified using nickel column chromatography
under denaturing conditions of 4 M guanidine. The purified
fusion protein was eluted from the column with a linear
gradient of 4 to 500 mM imidazole. Fractions containing
protein were dialyzed against water overnight, exchanging
with freshwater several times. The water-insoluble fusion
protein precipitate was collected by centrifugation.
The expressed fusion protein was designed with methion-
ine residues separating the insoluble KSI domain from the
inserted MUC1 peptide sequence, between each repeat of
the MUC1 peptide sequence, and before the histidine tag.
The fusion was digested with an excess of CNBr in 88%
formic acid under nitrogen gas overnight at room temperature
to cleave at all methionine residues and leave a homoserine
lactone at the C-terminus of all fragments. Formic acid was
removed by rotary evaporation, and the products were stirred
in distilled water. The insoluble KSI domain remained as a
precipitate, and was removed by centrifugation. The soluble
peptide cleavage products were lyophilized and resuspended
in a 90% H2O/10% acetonitrile mixture for HPLC purifica-
tion.
MUC1 peptides were purified using reverse-phase HPLC
on a prep scale radial compression C18 column (Alltech).
MUC1 peptides were eluted with a linear gradient of 10 to
95% acetonitrile. One major peak was observed in most
cases, which eluted with the same retention time as a standard
synthetic MUC1 peptide. Fractions containing purified
MUC1 peptides were collected, and the volatile solvents were
removed by rotary evaporation. The remaining aqueous
solutions lyophilized to give the pure peptide with a yield
of 17 mg of isotope-labeled peptide per liter of minimal
medium (50 mg/L for unlabeled peptide in LB medium).
Fluorescence Binding Measurements. Fluorescence mea-
surements were used to determine the equilibrium dissocia-
tion constants (KD) and kinetic off rates (k-1) for the binding
of the MUC1 16mer and 40mer peptides to Fab B27.29. Fab
B27.29 (0.86µM stock solution) was titrated with small
aliquots of peptide to a final concentration that was more
than 200-fold in excess of the Fab concentration. The change
in Fab fluorescence intensity was monitored, and the
concentration of bound ligand was calculated (percent of
maximum fluorescence change). The natural log of the free
ligand concentration was plotted against the concentration
of the bound ligand, and the curve was fit to eq 1
according to Michaelis-Menten kinetics, where the capacity
is the concentration of the Fab andKD is the equilibrium
dissociation constant.
Titration of Fab with Peptides. Samples for NMR
spectroscopy were dissolved in 90% H2O, 10% D2O PBS,
1 mM DSS, and 0.01% NaN3 and adjusted to pH 7.1
(uncorrected for D2O concentration). Titrations were per-
formed on samples containing 200µM Fab B27.29 (by
mass), with the MUC1 16mer peptide at 40, 80, 140,
200, 500, 800, and 1600µM and the 40mer peptide at 80,
160, 240, 320, 400, 800, and 1200µM. Peptide was added
from concentrated 30 mM stock solutions to minimize
dilution of the Fab sample. At the final titration point, dilution
of the Fab sample was less than 5%. The concentrations of
the stock peptide solutions were determined by comparing
the one-dimensional (1D) NMR integration of peptide peaks
relative to an external DSS standard that was calibrated
against the primary standard potassium hydrogen phthalate.
At each titration point,1H NMR spectra were obtained, as
well as1H-15N HSQC and1H-13C HSQC spectra. At select
titration points,15N T1, 15N T2, {1H}-15N NOE,13CR T1, and
13CR T1F measurements were also taken. The{1HR}-13CR
NOE data sets were obtained by lyophilizing the samples
and resuspending them in 99.9% D2O to aid in water
suppression.
NMR Experiments. Most NMR experiments were per-
formed on a Varian Inova 500 MHz spectrometer at 5°C.
Triple-resonance and15N-edited NOESY-HSQC experi-
ments to identify Fab-bound peptide resonances were
carried out on a Varian Inova 750 MHz spectrometer at 5
°C. All NMR spectra were referenced to DSS at 0 ppm.
Proton NMR resonances were assigned as previously re-
ported (37). Carbon and nitrogen resonances were assigned
using the known proton chemical shifts in the1H-15N HSQC
and1H-13C HSQC spectra, as well as a three-dimensional
(3D) 1H-15N NOESY-HSQC experiment. 1D1H NMR
spectra were acquired at 5°C, with a spectral width of 7000
Hz, using 32 000 acquired points.1H-15N HSQC spectra
were typically acquired using a spectral width of 1114 Hz
and 32 points int1 and a spectral width of 7000 Hz and 2048
points int2. 1H-13C HSQC spectra ofR-carbon-proton pairs
were typically acquired using a spectral width of 3000 Hz
and 48 points int1 and a spectral width of 7000 Hz and
2048 points int2. Relaxation experiments utilized similar
parameters.15N T1 experiments recorded spectra with
relaxation delays of 10.3, 51.3, 102.5, 153.8, 205, 307.5, and
410 ms, with duplicate experiments recorded for the 51.3
ms data point to confirm our error estimates.13CR T1
experiments recorded spectra with relaxation delays of 10,
50, 100, 150, 200, and 300 ms, with the 100 ms data set
duplicated for confirmation of error estimates.15N T2
experiments recorded spectra with relaxation delays of 14.4,
28.8, 57.6, 86.4, 115.2, 144, and 158.4 ms, with a duplicate
data set at 57.6 ms.13CR T1F experiments recorded spectra
with relaxation delays of 10, 20, 40, 60, 100, 150, 200, and
250 ms, with the 40 ms data set duplicated for confirmation
of error estimates. Steady-state{1H}-15N NOE and{1HR}-
13CR NOE experiments were performed with and without a
3 s presaturation period. During this presaturation period,
[bound]) (capacity[free ligand])/(KD + [free ligand])
(1)





































































proton frequencies were irradiated with a continuous low-
power pulse. In the experiment without presaturation, the
low-power irradiation was replaced with a delay period of 3
s. The NOE values were calculated as the ratio of peak
intensities in the experiments with and without proton
presaturation. Pulse sequences were utilized as reported
previously (42, 43).
Triple-resonance HNCACB (44) and CBCA(CO)NNH
(45) experiments were performed at 750 MHz to assign the
bound peptide resonances that appeared in the Fab-bound
spectra. The MUC1 16mer peptide was used for these
experiments because of its spectral simplicity. The MUC1
16mer (250µM) was added to Fab B27.29 (200µM)
to achieve the highest intensity for the Fab-bound reso-
nances without complicating the spectra with resonances
from the free MUC1 16mer. Two-dimensional (2D) ver-
sions of the HNCACB and CBCA(CO)NNH experi-
ments were employed, because under the sample conditions
that were used, and with the greater spectral dispersion of
the higher magnetic field strength of 750 MHz, the amide
protons of interest were resolved from all other reso-
nances. The HNCACB experiment was carried out using
1000 transients and 1024 complex points in the acquired
dimension, 120 complex points in the indirect carbon
dimension, and sweep widths (750 MHz) of 15 100 Hz for
carbons and 10 500 Hz for protons. The CBCA(CO)NNH
experiment was carried out using 2048 transients and 1024
complex points in the acquired dimension, 80 complex
points in the indirect carbon dimension, and sweep widths
(750 MHz) of 11 000 Hz for carbons and 10 500 Hz for
protons. In addition, a 2D15N-edited NOESY-HSQC
experiment was carried out at 750 MHz on the same
MUC1 16mer-Fab B27.29 sample. This experiment uti-
lized 1216 transients and 1024 complex points in the acquired
dimension, 188 points in the indirect proton dimension,
and sweep widths (750 MHz) of 7500 Hz for the indirect
proton and 10 500 Hz for the acquired proton dimen-
sions.
Data Processing and Analysis. All 2D data sets were
processed on a Silicon Graphics O2 workstation using the
NMRPipe System software (46). In both dimensions, 2D
data sets were multiplied by a 90°-shifted squared sine bell
and zero-filled prior to Fourier transformation.T1 and T2
values were determined using nonlinear least-squares fitting
of the measured peak heights to a two-parameter exponential
decay, also within the NMRPipe package. Uncertainties in
the calculatedT1 andT2 values from the least-squares fitting
were determined by the signal-to-noise ratio of individual
peaks in each of theT1 andT2 experiments (42, 43). Two
groups have recently shown error estimates from least-
squares fitting to be unreasonably small, and have used the
value of 5% as a more realistic value (47, 48). Therefore,
we have set the error in the calculatedT1 andT2 to 5% of
the values.
Reduced Spectral Density Mapping. Reduced spectral
density mapping is a convenient method for characterizing
the motion of each N-H bond atJ(0), J(ωN), and J(ωH)
frequencies (49, 50). The spectral densities at these three
frequencies can be obtained from relaxation ratesR1 (1/T1)
andR2 (1/T2) and the steady-state heteronuclear NOE using
eqs 2-4.
For the above equations,d ) [µ0h(γNγH)/8π2]〈1/rNH3〉 andc
) (ωN/31/2)(σ|| - σ⊥), and ωN and ωH are the Larmor
frequencies of the15N and1H nuclei, respectively.
RESULTS
Assignment of Resonances. 1H, 15N, and 13C resonance
assignments for the15N- and13C-labeled recombinant MUC1
16mer and 40mer peptides are shown in Table S1 of the
Supporting Information.
Fluorescence Binding Measurements. The equilibrium
dissociation constant (KD) for a ligand binding to a macro-
molecule is equal to the ratio of the intrinsic kinetic on (k1)
and off (k-1) rate constants.
Fluorescence binding measurements were used to determine
theKD, k-1, and stoichiometry for the binding of the MUC1
16mer and 40mer peptides to Fab B27.29. These experiments
yielded aKD of 10.9 ( 0.4 µM for the 16mer and aKD of
11.1( 0.5µM for the 40mer, with 1:1 binding stoichiometry
measured in each case.
Exchange Time Scales of MUC1 Peptide-Fab B27.29
Binding. Using theKD values measured from the fluorescence
binding titrations, we have attempted to establish off-rates
and time scales for the binding of the MUC1 16mer and
40mer peptides to Fab B27.29, a prerequisite for accurate
NMR data interpretation. Surface plasmon resonance experi-
ments in other systems indicate that a diffusion-controlled
on rate (108 M-1 s-1) is not a valid assumption for a flexible
peptide binding to solution-state Fab. On the basis of
estimates for similar complexes (51-54), we therefore
assume a value of 106-107 M-1 s-1 for the kinetic association
ratek1. Combining this value with the measured equilibrium
binding constantKD (eq 5) gives a kinetic dissociation rate
k-1 of 10-100 s-1.
The first relevant NMR time scale to be considered is the
chemical shift time scale. Intermediate exchange on the
chemical shift time scale (k-1 ∼ ∆δ)2 is expected for the
majority of peptide resonances in the MUC1-B27.29
complex, as ak-1 of 10-100 s-1 is within the range of the
typical differences between free and bound chemical shifts
[∆δ ) 100-1000 Hz (55)]. In this regime, MUC1 peptide
resonances are not expected to shift with varying concentra-
tion of ligand, but instead experience a loss in signal intensity
due to line broadening (55). However, the MUC1-B27.29
system is additionally complicated due to portions of the
peptide coexisting on different exchange time scales, con-
tingent on the relative magnitudes of the∆δ terms (which
vary across the peptide sequence). For example, peptide
2 ∆δ represents the difference between the frequencies of the
exchanging free and bound peptide resonances (∆δ ) |δB - δF|).
J(ωH) ) [4/(5d
2)](γN/γH)(NOE - 1)/T1 (2)
J(ωN) ) [1/T1 - (7d
2/4)J(ωH)]/(3d
2/4 + c2) (3)
J(0) ) [1/T2 - (3d
2/8 + c2/2)J(ωN) -
(13d2/8)J(ωH)]/(d










































































resonances belonging to the Fab binding epitope residues
PDTRPAP, which are expected to have the largest∆δ erms,
may experience slow exchange on the chemical shift time
scale (k-1 , ∆δ). In this regime, distinct free and bound
MUC1 peptide resonances would be expected at their
respective chemical shifts. Conversely, smaller∆δ values
for resonances at the MUC1 peptide termini could well
translate into fast exchange on the chemical shift time scale
(k-1 . ∆δ). This third regime, if present, would be
characterized by a single MUC1 peptide resonance at the
population-weighted average of the free and bound chemical
shifts. Thus, we anticipate a mixture of exchange regimes
for MUC1 peptide resonances in an HSQC-monitored Fab
B27.29 titration, marked by complex spectral behavior.
Another relevant NMR time scale to be considered is the
relaxation time scale. Relaxation parameters such as the
spin-lattice relaxation rate (R1), spin-spin relaxation rate
(R2), and steady-state heteronuclear NOE are characterized
by rate differences between their free and bound states that
are smaller than those associated with chemical shift. For
example, typical differences cited in the literature are 0.1-
10 Hz forR1, 1-50 Hz forR2, and 0.1-5 Hz for NOE (55).
Thanks to these faster time scales, ak-1 of 10-100 s-1 puts
the MUC1 peptide-Fab system in the fast exchange limit
with respect to spin relaxation (k-1 . R1B, whereR1B )
1/T1B, the spin-lattice relaxation rate of the bound state).
In this regime, relaxation properties of the bound state are
transferred to the resonances of the free state, and the
observedR1 is a population-weighted average of the free and
boundR1 values [eq 6 (56)].
The same principle allows implementation of the TRNOESY
experiment (57). We have previously shown that the MUC1
peptide experiences a significant transferred NOESY effect
upon binding to Fab B27.29 (37), providing further credence
that the system is in fast exchange with respect to the NMR
relaxation time scale.
The existence of two exchange regimes for the MUC1
system, intermediate on the chemical shift time scale, but
fast on the relaxation time scale, allows dynamics information
to be obtained for the bound state, regardless of whether an
averaged resonance is monitored (fast exchange on the
chemical shift time scale), an exchange-broadened resonance
is monitored (intermediate exchange on the chemical shift
time scale), or separate free and bound resonances are
monitored (slow exchange on the chemical shift time scale).
An interesting corollary of this condition is that these separate
free and bound MUC1 resonances should also manifest the
same line width, as line widths are largely dependent on
spin-spin relaxation rates, and these rates are population-
weighted averages in the limits of fast exchange with respect
to relaxation.
15N HSQC-Monitored Titrations of MUC1 Peptides with
Fab B27.29. Panels A and C of Figure 1 present the15N-
edited HSQC spectra acquired for the15N- and13C-labeled
16mer and 40mer MUC1 peptides, respectively, in the
absence of Fab B27.29. A cursory examination of these
spectra reveals that the chemical shifts for residues APDTR-
PAPGSTA are almost identical for the two peptides (i.e.,
the peaks representing A5-A16 in the 16mer sequence are
roughly superimposable with the peaks representing A4-
A15 in the 40mer sequence). This suggests that the PDTR-
PAP epitope regions in the 16mer and 40mer explore similar,
if not identical, conformational space. Further examination
of just the 40mer HSQC spectrum (Figure 1C) reveals that
the peaks corresponding to residues PDTRPAPGSTA (D6/
16-A18/38) are chemical shift degenerate, indicating that
the conformational space explored by the core peptide
epitope is identical from one repeat to the next. A full
characterization of the dependence of MUC1 structure and
dynamics on the number of repeat sequences is presented
elsewhere (58). However, previous1H NMR studies pub-
lished by this group have identified a well-populated type I
â-turn spanning residues PDTR within the PDTRPAP epitope
region (37, 38, 58). As theâ-turn is a common structural
motif in antigenic regions of proteins (59), and is commonly
found in NMR and crystal structures of antibody-antigen
complexes (60-63), the presence of aâ-turn within the
MUC1 B-cell epitope may explain the immunodominance
of this region.
Panels B and D of Figure 1 present the15N-edited HSQC
spectra acquired for the15N- and 13C-labeled 16mer and
40mer MUC1 peptides, respectively, in the presence of Fab
B27.29. These spectra correspond to the first titration point
with a molar ratio of peptide to Fab of greater than unity
([peptide]/[Fab]> 1), a point at which resonances for the
significantly exchange broadened residues within the PDTR-
PAP epitope region could begin to be detected. These
resonances correspond to D7, T8, R9, A11, and G13 within
the 16mer (boxed in Figure 1B) and D6/26, T7/27, R8/28,
A10/30, and G12/32 within the 40mer (boxed in Figure 1D),
an identical collection of residues that indicates an identical
mode of epitope recognition and binding in the one-repeat
and two-repeat systems.
As predicted, complex spectral behavior is observed in
panels B and D of Figure 1, marked by a mixture of chemical
shift exchange time scales. For example, extensive line
broadening consistent with an intermediate exchange time
scale (k-1 ∼ ∆δ) renders the PDTRPAP resonances unob-
servable until the Fab is saturated ([peptide]/[Fab]> 1) and
a significant pool of free peptide is allowed to build up. In
contrast, MUC1 residues outside the PDTRPAP epitope
sequence display sizable peaks, even when [peptide]/[Fab]
< 1(see Figure 2A,B), at which point all of the peptide would
be expected to be in the Fab-bound pool. The intensities of
these peaks increase with an increasing concentration of
peptide, and resonate at or near their free chemical shifts
(∆δ ∼ 0), implying no change in the chemical environment
upon Fab binding and therefore little or no contact with the
antibody-combining site. This behavior is consistent with fast
exchange on the chemical shift time scale (k-1 . ∆δ), as
predicted for residues at the MUC1 peptide termini.
Finally, Figure 1B shows one of several new peaks in the
Fab-bound spectrum of the 16mer (marked with an asterisk
in the spectrum). These peaks appear at the lowest concen-
trations of MUC1 peptide, and increase in intensity with
peptide concentration until the Fab is saturated with peptide,
and the free peptide peaks of the bound epitope sequence
begin to appear in the spectrum (see Figure 2). In other
words, these new bound peptide peaks display classic slow
exchange titration behavior. Similar bound resonances are
R1obs) PBR1B + PFR1F (6)





































































also seen in the1H-15N HSQC spectrum of the 40mer. As
these new 16mer peaks are absent in the free peptide
spectrum, they must correspond to a set of bound peptide
resonances that experiences slow exchange on the chemical
shift time scale (k-1 , ∆δ). Interestingly, only two new
bound peptide resonances are observed with strong intensity,
not four bound peptide resonances as might be expected since
the PDTRPAP epitope sequence contains four non-proline
residues. Therefore, these two bound peptide resonances must
represent a subset of residues within the peptide epitope that
experience the greatest change in chemical environment upon
Fab binding (the largest∆δ terms), and thus the most
intimate contact with the antibody-combining site. To probe
further the identities of these bound peptide resonances,
triple-resonance experiments were performed. Although
chemical exchange broadening of most epitope resonances
within the PDTRPAP sequence prohibits complete assign-
ment of the observed bound-state resonances, the triple-
resonance experiments confirm that the new peak at 8.51
ppm in the1H-15N HSQC spectrum of the 16mer (marked
with an asterisk in Figures 1B and 2) is from R9. This
conclusion is supported by mutational analysis demonstrating
that the presence of R9 in the MUC1 sequence is necessary
for binding to other breast and ovarian cancer antibodies (12).
13C HSQC-Monitored Titrations of MUC1 Peptides with
Fab B27.29. The13C-edited HSQC spectra acquired for the
15N- and 13C-labeled 16mer and 40mer MUC1 peptides in
the absence (Figure 3A,C) and presence (Figure 3B,D) of
Fab B27.29 are also shown. These13C-edited HSQC spectra
provide chemical shift information for the many proline
residues in the MUC1 sequences, as well as for select side
chain resonances. As previously noted for Figure 1, AP-
DTRPAPGSTA backbone and side chain resonances are
chemical shift degenerate in the 16mer versus the 40mer
pectra, and from one repeat to the next in the 40mer spectra.
Consistent with the15N-edited HSQC-monitored titration is
the appearance of exchange-broadened13C peptide reso-
nances for [peptide]/[Fab] molar ratios of>1 (Figure 3B,D).
FIGURE 1: 1H-15N HSQC spectra of (A) 800µM MUC1 16mer free in solution, (B) 500µM 16mer with 200µM Fab B27.29, (C) 800
µM 40mer free in solution, and (D) 320µM 40mer with 200µM Fab B27.29. Boxed cross-peaks experience the greatest losses in signal
intensity due to line broadening in the presence of Fab. The spectra for the peptide with or without Fab were recorded at 500 MHz on a
Varian Inova 500 NMR spectrometer. NMR samples were in PBS buffer (pH 7.1) and 90% H2O/10% D2O at 5.0°C.





































































These resonances correspond to P6, D7, T8, R9, P10, A11,
P12, and G13 within the 16mer (boxed in Figure 3B) and
P5/25, D6/26, T7/27, R8/28, P9/29, A10/30, P11/31, and
G12/32 within the 40mer (boxed in Figure 3D), an identical
collection of residues that indicates identical binding epitopes
in the one-repeat and two-repeat systems.
Taken together, the results of the15N-edited and13C-edited
HSQC-monitored titrations are consistent and complemen-
tary. The exchange broadening observed for the PDTRPAP
residues demonstrates selective interactions of this region
of the sequence with Fab B27.29, in agreement with the
epitope mapping of B27.29 provided by ELISA binding
studies (64). Significantly, earlier NMR studies by this group
have identified a type Iâ-turn spanning residues PDTR
within the PDTRPAP epitope region of both the 16mer and
the 40mer (37, 38, 58). These same studies also identified a
second less well-definedâ-turn in the 40mer, spanning
residues GSTA immediately downstream of the peptide
epitope region (58). However, the studies presented here
demonstrate that only the glycine residue from the GSTA
sequence (G13 in the 16mer and G12/32 in the 40mer) is
exchange broadened in the presence of Fab. These results
point to the specificity of the antibody as recognizing
uniquely the PDTRPAP sequence, and not just generalâ-turn
structure.
15N NMR Relaxation Measurements. Once enough peptide
was added to obtain sufficient intensity for the PDTRPAP
resonances ([peptide]/[Fab]. 1), NMR relaxation experi-
ments were performed to probe the dynamics of the system.
These experiments included the measurement of15N T1 and
T2 relaxation rates and steady-state heteronuclear{1H}-15N
NOEs for the15N- and13C-labeled 16mer and 40mer MUC1
peptides in the absence and presence of Fab B27.29. The
values of these relaxation parameters are given in Tables
S2-S4 of the Supporting Information. The15N T1 relaxation
data from these tables are plotted in panels A (16mer with
or without Fab) and B (40mer with or without Fab) of Figure
4.
In general, the15N T1 andT2 values acquired for the 16mer
and 40mer MUC1 peptides become shorter in the presence
of Fab, consistent with an overall increase in the correlation
time of the peptides as they are bound to antibody. For
example, the averaged15N T1 value of the 16mer across the
entire sequence (〈T1〉) equals 767 ms in the absence of Fab,
but 〈T1〉 ) 508 ms in the presence of Fab (800µM 16mer
and 200µM Fab B27.29, or [peptide]/[Fab]) 4). The
corresponding15N T1 values for the 40mer (〈T1〉) are 669
and 539 ms in the absence and presence, respectively, of
the same relative ratios of Fab. TheseT1 values show
titration-dependent behavior (see panels A and B of Figure
4), in that an increase in the [peptide]/[Fab] ratio leads to a
corresponding increase in the15N T1 value measured for each
residue in the peptide sequence. This concentration-depend-
ent behavior demonstrates that the MUC1 peptide-Fab
B27.29 complex experiences fast exchange behavior on the
NMR relaxation time scale, and thus, the measured15N T1
values are population-weighted averages of the free and
bound states (see eq 6). Under these conditions, relaxation
measurements made for exchange-broadened or even “free-
state” peptide resonances (i.e., exchange being intermediate
to slow on the chemical shift time scale) will nevertheless
yield information relevant to the dynamics of the bound state.
Thus, Fab-induced changes in the measured relaxation
parameters can be interpreted within the context of Fab-
induced changes to the backbone dynamics of the MUC1
peptides as these peptides are bound and immobilized within
the B27.29-combining site.
13C NMR Relaxation Measurements. While the15N NMR
relaxation measurements discussed above provide evidence
of fast exchange on the relaxation time scale, the Fab-induced
FIGURE 2: 1H-15N HSQC titration of 200µM Fab B27.29 with MUC1 16mer peptide: (A) 40µM 16mer, (B) 200µM 16mer, (C) 500µM
16mer, and (D) 800µM 16mer. The Fab-bound peptide resonances are marked with asterisks, and increase in intensity until a peptide:Fab
ratio of greater than 1:1 is reached. At a peptide:Fab ratio of greater than 1:1, the resonances of the MUC1 epitope sequence begin to
appear, while the bound resonances do not increase in intensity. Notice that the resonances for Thr3 and Ser4 (near the end of the MUC1
peptide and outside the epitope sequence) have strong intensity throughout the titration. The spectra for the peptide with or without Fab
were recorded at 500 MHz on a Varian Inova 500 NMR spectrometer. NMR samples were in PBS buffer (pH 7.1) and 90% H2O/10% D2O
at 5.0°C.





































































changes measured for individual relaxation parameters (T1,
T2, and NOE) are fairly uniform across the MUC1 peptide
sequence. The limited sequence resolution afforded by the
15N nucleus arises from the magnetic susceptibility of the
15N-1H bond vector to a variety of environmental influences,
including changes in solvent exposure and solvent exchange.
In contrast, the magnetic susceptibility of the13CR-1HR bond
vector is uniquely sensitive to changes in local backbone
conformation and chemical environment. Thus,13C NMR
relaxation measurements can provide high-resolution, se-
quence-specific information about Fab-induced changes to
the backbone dynamics of the MUC1 peptides, allowing a
precise mapping of the boundaries of the peptide epitope
recognized and bound by Fab B27.29.13CR T1 and T1F
relaxation rates and steady-state heteronuclear{1HR}-13CR
NOEs were therefore also measured for the15N- and 13C-
labeled 16mer and 40mer MUC1 peptides in the absence
and presence of Fab B27.29. The values of these relaxation
parameters are presented in Tables S2- 4 of the Supporting
Information.
Of the three parameters that were measured (T1, T1F, and
NOE), theT1 parameter arguably provides the best probe of
local nanosecond to picosecond time scale dynamics, as it
contains no exchange contributions,3 nor does it suffer from
low signal-to-noise or propagated error.4
Figure 5 therefore only presents the13CR T1 measured for
the 16mer (panel A) and 40mer (panel B) MUC1 peptides
in the absence (squares) and presence (circles) of Fab B27.29.
In the presence of Fab, significant decreases inT1 (>50 ms)
are observedonly for residues A5, P6, D7, R9, P10, A11,
and P12 in the 16mer and P5/25, D6/26, T7/27, and R8/28
3 The paramaters that measure transverse magnetization,T1F andT2,
contain a contribution from exchange between the free and bound state,
according to the equationR2obs ) PBR2B + PFR2F + PBPF(τ)(2π∆δ)2,
whereτ ∼ 1/k-1 (compare to the analogous expression forR1obsshown
in eq 6).
4 The steady-state heteronuclear NOE is calculated from difference
spectra (with and without1H saturation), so experimental errors are
summed. In addition, the spectrum acquired without1H saturation often
suffers from a low to signal-to-noise ratio, contributing a significant
error to the final calculated NOE.
FIGURE 3: 1H-13C HSQC spectra of (A) 800µM MUC1 16mer free in solution, (B) 500µM 16mer with 200µM Fab B27.29, (C) 800µM
40mer free in solution, and (D) 200µM 40mer with 200µM Fab B27.29. Boxed cross-peaks experience the greatest losses in signal
intensity due to line broadening in the presence of Fab. The spectra were recorded at 500 MHz on a Varian Inova 500 NMR spectrometer.
NMR samples were in PBS buffer (pH 7.1) and 90% H2O/10% D2O at 5.0°C.





































































in the 40mer, indicating increases in the local correlation
times of these PDTRPAP core epitope residues as they are
bound and immobilized within the B27.29-combining site.
That this collection of “bound and immobilized residues”
differs somewhat between the two peptides (PDTR for the
40mer and APDTRPAP for the 16mer) is not a reflection of
different binding modes. Rather, the disparity between the
epitope profiles detected in the 16mer and the 40mer arises
from the overlap of alanine and proline peaks in the 40mer
T1 spectra, which leads to averagedT1 values measured for
P9/29, P16/36, and P17/37, and for A4/24, A10/30, and A15/
35 in the 40mer, and therefore artifically elevated values for
P9/29 and A10/30 within the PDTRPAP core epitope. Thus,
the epitope profile detected from the 16merT1 experiment
probably best represents the true boundaries of the peptide
epitope recognized and bound by Fab B27.29 (APDTRPAP),
a profile which very closely matches that identified from
earlier indirect ELISA-based experiments (PDTRPAP)
(10-15).
Spectral Density Analysis. Raw relaxation rates are usually
analyzed within the context of a relaxation formalism that
can provide simplified motional models, as well as some
insight into the time scales and amplitudes of internal
motions. One such formalism is the model free approach of
Lipari and Szabo (65, 66), which provides a means of
assessing the contributions of internal motions and confor-
mational exchange to spin relaxation. However, there are
limitations to this approach that arise from inherent assump-
tions. The overall molecular reorientation must be isotropic
and independent of fast internal motions (which contribute
negligibly to measured relaxation). These assumptions do
not hold for small flexible peptides, like the MUC1 peptides,
which can experience a broad range of motional time scales.
An alternative relaxation analysis approach for character-
izing molecular dynamics is provided by spectral density
analysis (49, 50) which has an advantage in that it makes
no assumptions about the separability of the time scales
between the motions, and allows the possibility of sizable
contributions to relaxation from high-frequency motions.
Moreover, this methodology is analytic and independent of
error estimates. In general, the spectral density atJ(0) is
proportional to the local correlation time of the backbone
nitrogen (67). Thus, it is possible to interpret Fab binding-
induced chances inJ(0) on the basis of changes in local
correlation times. However, this interpretation is valid only
in the absence of conformational exchange phenomena,
FIGURE 4: 15N T1 relaxation times measured for (A) 800µM MUC1 16mer free in solution (9), 1600µM 16mer with 200µM Fab B27.29
(2), and 800µM 16mer with 200µM Fab B27.29 (b) and (B) 800µM 40mer free in solution (0), 1200µM 40mer with 200µM Fab
B27.29 (4), and 800µM 40mer with 200µM Fab B27.29 (O). All measurements were taken at 500 MHz on a Varian Inova 500 NMR
spectrometer. NMR samples were in PBS buffer (pH 7.1) and 90% H2O/10% D2O at 5.0°C. Standard deviations calculated for each
parameter are plotted as error bars.
FIGURE 5: 13CR T1 relaxation times measured for (A) 800µM MUC1 16mer free in solution (9) and 800µM 16mer peptide with 200µM
Fab B27.29 (b) and (B) 40mer free in solution (0) and 800µM 40mer peptide with 200µM Fab B27.29 (O). All measurements were taken
at 500 MHz on a Varian Inova 500 NMR spectrometer. NMR samples were in PBS buffer (pH 7.1) and 90% H2O/10% D2O at 5.0°C.
Standard deviations calculated for each parameter are plotted as error bars.





































































which can lead to shortening ofT2 times, and therefore larger
values of J(0) (68). Therefore, the contribution of slow
exchange motions (microseconds to milliseconds) toJ(0)
must also be considered in spectral density analysis.
Using eqs 2-4 from Materials and Methods, theJ(ω)
spectral density values [J(0), J(ωN), and J(ωH)] were
calculated from the15N T1 and T2 relaxation rates and the
steady-state heteronuclear{1H}-15N NOEs measured for the
15N- and13C-labeled MUC1 16mer and 40mer peptides free
in solution versus those bound to Fab B27.295 (see Tables
S2-S4 of the Supporting Information). These values are
shown in Figure 6, which plots theJ(0) (panels A and B)
and J(ωN) (panels C and D) values only (see Table S5 of
the Supporting Information for the raw values). The free
peptideJ(0) (squares) yield average values across the entire
sequence [〈J(0)〉] of 0.53 ns rad-1 for the 16mer and 0.78 ns
rad-1 for the 40mer, consistent with the longer global
correlation time of the larger two-repeat peptide. In com-
parison, the averageJ(0) value for the PDTRPAP epitope
sequence [〈J(0)〉epitope] is 0.57 for the 16mer and 0.79 for the
40mer. Thus, the epitope sequences are not especially ordered
relative to other parts of the sequence, at least in the free
solution states of these peptides.
Addition of Fab (Figure 6, circles) leads to significant
increases in theJ(0) values measured across the 16mer and
40mer sequences, commensurate with increases in the global
correlation times experienced by these peptides as they are
bound to antibody. These increases inJ(0) are not uniform
across the length of the peptides, being the most pronounced
for residues within the PDTRPAP epitope region. For
example,〈J(0)〉 for the entire 16mer sequence increases from
0.53 to 2.8 ns rad-1 (an increase of∼2.3 ns rad-1), whereas
〈J(0)〉epitopefor just the PDTRPAP epitope within the 16mer
increases from 0.57 to 3.9 ns rad-1 (an increase of∼3.3 ns
rad-1). Similarly, 〈J(0)〉 for the entire 40mer sequence
increases from 0.78 to 1.8 ns rad-1 (an increase of∼1.0 ns
rad-1), whereas〈J(0)〉epitopeincreases from 0.79 to 2.2 ns rad-1
(an increase of∼1.4 ns rad-1).6 These substantially elevated
〈J(0)〉epitope values are consistent with significant increases
in the local correlation times of residues that directly contact
5 The reduced spectral density mapping approach assumes that the
high-frequency spectral density terms are approximately equal in
magnitude, i.e.,J(ωH ( ωN) ≈ J(ωH), and may therefore be replaced
by a single equivalent term,J(ωH) (47, 48). This assumption does not
hold for 13C NMR relaxation, whereJ(ωH ( ωC) cannot be expected
to equalJ(ωH). Thus, reduced spectral density terms were calculated
only for the15N NMR relaxation data set.
6 The stoichiometry of a 1:1 complex of 40mer and Fab results in
an average of one bound 40mer epitope and one free 40mer epitope.
Thus, the smaller increases inJ(0) measured for the 40mer versus the
16mer (at the same molar ratios of Fab to peptide) may be a result of
the doubled effective ligand concentration of the 40mer, which
presumably leads to aJ(0) value averaged between the one bound
epitope and the one free epitope in the two-repeat peptide.
FIGURE 6: J(0) andJ(ωN) spectral density values calculated from15N NMR relaxation data measured for (A and C) 800µM MUC1 16mer
free in solution (9) and 800µM 16mer with 200µM Fab B27.29 (b) and (B and D) 800µM MUC1 40mer free in solution (0) and 800
µM 40mer with 200µM Fab B27.29 (O). NMR samples were in PBS buffer (pH 7.1) and 90% H2O/10% D2O at 5.0°C. Standard deviations
calculated for each parameter are plotted as error bars.





































































the antibody, well in excess of the uniform increases in global
correlation time expected as a result of binding. Thus, the
J(0) spectral density terms calculated from15N NMR
relaxation experiments are sensitive indicators of specific
epitope-antibody interactions across the molecular interface,
even if the constituent relaxation parameters (T1, T2, and
NOE) appear to provide a less well-resolved picture upon
first analysis.
As previously mentioned, conformational exchange pro-
cesses on slow time scales can artificially elevate the value
of J(0) (68). However, these slow time scale motions have
a negligible effect on the calculated values of theJ(ωN) and
J(ωH) spectral densities, as these represent only high-
frequency motions (49, 69, 70). Figure 6 (panels C and D)
plots theJ(ωN) values calculated from the relaxation data
presented in Table S5 of the Supporting Information. A
comparison of theJ(ωN) and J(0) plots reveals the same
pattern of increases for PDTRPAP epitope residues, sup-
porting our interpretation of increased local correlation times
for these epitope residues upon antibody binding, and further
confirming that exchange effects do not dominate the
observed increases inJ(0). Most importantly, the quality of
the J(ωN) and J(0) data presented for the MUC1 system
illustrates the utility of spectral density analysis in epitope
mapping, even in the presence of slow chemical exchange.
Peptide Epitope Mapping.In the study presented here, two
different classes of isotope-edited NMR experiments have
been used to map the binding of Fab B27.29 to one- and
two-repeat MUC1 peptides: (1) HSQC-monitored titrations
that measure exchange broadening, and therefore the relative
magnitude of the Fab-induced chemical shift, and (2) NMR
relaxation measurements that measure changes in the pico-
second to nanosecond time scale motions in the peptide
backbone as a function of Fab-induced increases in local
correlation time. A comparison of the 40mer peptide epitope
profiles obtained from1H-15N HSQC-monitored spectral
analysis versus15N NMR relaxation analysis is presented in
Figure 7. The top panel (panel A) plots differences in the
HSQC peak intensities (∆I) as a consequence of Fab-induced
chemical shifts, whereas the bottom two panels (panels B
and C) plot differences in the low- and high-frequency
spectral density values [∆J(0) and∆J(ωN)] as a consequence
of Fab-induced increases in local correlation time. As
expected, these profiles show very similar trends, indicating
that changes in the chemical environment track changes in
local dynamics. Thus, regions of the 40mer peptide backbone
that experience a marked change in chemical environment
upon binding to B27.29 also show significant decreases in
picosecond to nanosecond time scale motions as they become
immobilized within the antibody-combining site. The con-
sistency and complementarity of the information provided
by these two independent NMR observables (chemical shift
and spin relaxation) illustrate the power of a direct spectro-
scopic approach in peptide epitope mapping, especially if it
can provide additional structural and dynamical information
that is useful in peptide vaccine design.
CONCLUSIONS
We have developed an approach utilizing NMR relaxation
measurements and heteronuclear correlation experiments to
map antibody epitopes. These NMR experiments allow a
direct, sequence-specific probe of binding, and clearly
demonstrate which parts of the MUC1 peptide epitope are
immobilized upon binding antibody. We apply this technique
to determining the epitope of an antibody raised against
tumor cells for the purposes of designing a cancer vaccine.
Our method uses the antibody epitope as an indirect probe
of a structural and/or dynamic state present on the tumor
cell surface, and as a probe of the peptide state that is
immunogenic. Our approach to vaccine design is of general
utility for any antigen that lacks sufficient analytical char-
acterization, as is the case with most tumor-associated
antigens.
In this study, we provide direct spectroscopic evidence
that the MUC1 peptide sequence PDTRPAP, portions of
FIGURE 7: B27.29 epitope mapping of the MUC1 40mer peptide
from analysis of line broadening and relaxation data. (A) Differences
in the 1H-15N HSQC peak intensities (∆I) measured for 400µM
40mer with or without 200µM Fab (∆I ) I+Fab - I-Fab, where
I+Fab is the intensity of the peptide peak in the presence of Fab and
I-Fab is the intensity of the peptide peak in the absence of Fab).
Negative values of∆I indicate significant Fab-induced line
broadening; i.e.,I+Fab , I-Fab. (B) Differences in theJ(0) spectral
density values [∆J(0)] calculated from15N NMR relaxation data
measured for 400µM 40mer with or without 200µM Fab [∆J(0)
) J(0)+Fab - J(0)-Fab, whereJ(0)+Fab is theJ(0) calculated for the
peptide in the presence of Fab andJ(0)-Fab is theJ(0) calculated
for the peptide in the absence of Fab]. Increased values of∆J(0)
indicate significant Fab-induced increases in local correlation time;
i.e.,J(0)+Fab. J(0)-Fab. (C) Differences in theJ(ωN) spectral density
values [∆J(ωN)] calculated from15N NMR relaxation data measured
for 400 µM 40mer with or without 200µM Fab [∆J(ωN) )
J(ωN)+Fab- J(ωN)-Fab]. Fab-induced increases inJ(ωN) “track” Fab-
induced increases inJ(0).





































































which were identified from earlier ELISA-based experiments
as PDTRPA (10-15) and from our own previous homo-
nuclear NMR studies of MUC1 glycopeptides as PDTRP
(37), is bound and preferentially immobilized in the Fab
B27.29-combining site. Immobilization of the entire PDTR-
PAP sequence implies that the B27.29 epitope is continuous
and all residues in the epitope contribute to the binding
energy. Furthermore, we observe for the first time the bound-
state resonance of arginine within the PDTRPAP epitope
sequence. The observation of a bound-state resonance for
arginine suggests that this residue makes intimate contact
with B27.29, consistent with the mutational studies of Xing
et al. (12). In addition, we show that the residues in the
MUC1 sequence outside the boundaries of this defined
epitope remain highly flexible in the bound state, demon-
strating that they do not interact with antibody and extend
into solution out of the antibody-combining site.
The heteronuclear NMR relaxation experiments in this
study offer a significant increase in the amount of information
available relative to that from previous homonuclear NMR
experiments, in that individual proline resonances can now
be assigned and monitored with13C labels (these were
overlapped in the1H NMR spectrum), line broadening and
doubling of resonances in NMR-monitored titrations inter-
preted within the context of exchange time scales and peptide
backbone dynamics, and the limits of the peptide epitope
bound and immobilized within the antibody-combining site
more accurately mapped. Most importantly, analysis of15N
and 13C NMR relaxation data allows us to unequivocally
demonstrate that the line broadening observed in our NMR-
monitored titrations is a product of selective immobilization
of the peptide epitope in the Fab binding site. Future studies
will utilize the same heteronuclear NMR protocol to examine
contributions of MUC1 tumor-associated carbohydrate to
recognition by Fab B27.29. Those studies will allow a
determination of how the carbohydrate interacts with anti-
body, as well as an elucidation of how carbohydrate affects
the MUC1 peptide epitope.
Our characterization of the B27.29 epitope can be used to
increase the immunogenicity of MUC1 peptide vaccine
candidates. For example, since the MUC1 sequence outside
the PDTRPAP epitope retains its conformational heterogene-
ity in the Fab-bound state and is not important for binding,
it could be engineered for increased oral bioavailability, or
to act as a linker for multiple PDTRPAP epitopes or other
immunogenic peptide sequences. These changes could
significantly improve the efficacy of a MUC1 peptide-based
vaccine, while not altering the specificity of the immune
response. In addition, our results suggest that since the
PDTRPAP sequence is highly ordered in the antibody
binding site, preordering of the structure of the vaccine
candidate could increase the level of similarity with the
immunologically relevant MUC1 structure and therefore
increase immunogenicity. Future studies will continue to
probe the structure of the antibody-bound MUC1 peptide
sequence, with the ultimate goal of developing a second-
generation MUC1 peptide vaccine that better represents the
peptide portion of the tumor-associated MUC1 mucin.
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